Concepedia

Author

Suresh Anaganti

Institute for Experimental Endocrinology and Oncology

Also Known As

Anaganti, Suresh, Suresh Anaganti

13

Publications

990

Citations

9

H-Index

25

Concepts

All Affiliations

Institute for Experimental Endocrinology and OncologyCentre international de recherche sur le cancerAstraZeneca (United Kingdom)Bayer (United States)University of Naples Federico II
SA

About

Suresh Anaganti is an author at Institute for Experimental Endocrinology and Oncology specializing in medicine, cell biology, and breast cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

390

2

Cell Biology

4

4

138

3

Natural Sciences

1

1

40

4

Biochemistry

1

1

40

5

Endocrinology

1

1

34

Suresh Anaganti

×

9

Publications

986

Citations

9

H-Index

YearCitations

BAY 43-9006 Inhibition of Oncogenic RET Mutants

Francesca Carlomagno, Suresh Anaganti, Teresa Guida,

JNCI Journal of the National Cancer Institute

2006

471

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

Francesca Carlomagno, Teresa Guida, Suresh Anaganti,

Oncogene

2004

252

Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants

Teresa Guida, Suresh Anaganti, Livia Provitera,

Clinical Cancer Research

2007

72

Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474

Francesca Carlomagno, Teresa Guida, Suresh Anaganti,

Endocrine Related Cancer

2008

40

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines

Lynnette Fernandez‐Cuesta, Suresh Anaganti, Pierre Hainaut,

International Journal of Cancer

2010

39

Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines

Lynnette Fernandez‐Cuesta, Suresh Anaganti, Pierre Hainaut,

Breast Cancer Research and Treatment

2010

34

Functional characterization of a novel FGFR1OP‐RET rearrangement in hematopoietic malignancies

Daniela Bossi, Francesca Carlomagno, Isabella Pallavicini,

Molecular Oncology

2013

28

<i>In Vivo</i>and<i>in Vitro</i>Characterization of a Novel Germline RET Mutation Associated with Low-Penetrant Nonaggressive Familial Medullary Thyroid Carcinoma

Leonardo D’Aloiso, Francesca Carlomagno, Michele Bisceglia,

The Journal of Clinical Endocrinology & Metabolism

2006

25

p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines

Suresh Anaganti, Lynnette Fernandez‐Cuesta, Anita Langerød,

Cancer Letters

2010

25

Page 1